Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cybin Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health disorders. The company operates within the biotechnology and pharmaceutical research industries, with a primary emphasis on treatments for major depressive disorder (MDD), anxiety-related conditions, and other neuropsychiatric indications. Cybin’s core revenue drivers are research and development activities rather than commercialized products, as none of its drug candidates have yet received regulatory approval.
The company’s strategic positioning centers on improving the safety, efficacy, and scalability of psychedelic compounds through novel formulations and delivery technologies. Cybin was originally incorporated in Canada and is headquartered in Canada, with roots tracing back to its predecessor entity, Advancion Corporation, before rebranding and refocusing on psychedelic therapeutics in 2020. Its equity has traded under different symbols across exchanges; public disclosures most consistently reference trading on the NYSE American and Canadian markets, while the ticker “HELP” has appeared in certain historical or over-the-counter contexts. Data inconclusive based on available public sources regarding the current relevance of the “HELP” ticker.
Business Operations
Cybin’s operations are organized around its drug development pipeline, primarily within its psychedelic therapeutics research and development segment. The company generates operating activity through clinical trials, intellectual property development, and regulatory advancement of its proprietary compounds. Its lead programs include CYB003, a deuterated psilocybin analog in advanced clinical development for MDD, and CYB004, an investigational deuterated DMT program targeting anxiety disorders.
Operations span both domestic and international locations, with research, clinical trials, and administrative functions conducted in Canada, the United States, and the United Kingdom. Cybin controls a portfolio of patents related to novel psychedelic compounds, delivery methods, and dosing technologies. The company has expanded its technological capabilities through the acquisition of Adelia Therapeutics, which added proprietary DMT-related intellectual property to its pipeline, and through research collaborations with academic and technology partners.
Strategic Position & Investments
Cybin’s strategic direction emphasizes advancing late-stage clinical programs, securing intellectual property protection, and preparing for potential commercialization pathways pending regulatory approval. Growth initiatives are primarily focused on accelerating clinical trials for CYB003 and CYB004, while also exploring next-generation delivery systems designed to shorten treatment times and improve patient accessibility.
The company has made targeted investments in emerging psychedelic technologies rather than broad diversification. Notable strategic actions include the acquisition of Adelia Therapeutics and collaborations with neurotechnology and mental health research organizations. Cybin positions itself within the emerging psychedelic medicine sector by prioritizing compounds that can align with existing healthcare infrastructure, which it views as a competitive advantage relative to less standardized psychedelic treatment models.
Geographic Footprint
Cybin is headquartered in Toronto, Canada, and maintains a cross-border operational presence. Its primary corporate, regulatory, and capital markets activities are centered in North America, while significant research and clinical development efforts extend into the United States and the United Kingdom.
The company’s international footprint reflects its reliance on global clinical trial sites and regulatory pathways, particularly engagement with the U.S. Food and Drug Administration (FDA) and other international health authorities. While Cybin does not yet have commercial operations, its geographic reach is designed to support future market entry in major pharmaceutical markets across North America and Europe.
Leadership & Governance
Cybin was founded and is led by executives with backgrounds in pharmaceuticals, healthcare investment, and corporate development. The leadership team emphasizes a strategy of scientific rigor, regulatory alignment, and capital discipline as core elements of its governance philosophy.
Key executives include:
- Doug Drysdale – Chief Executive Officer
- Stefan Norberg – Chief Financial Officer
- Emiliano Moreno – Chief Clinical Officer
- Alexandra Varney – Chief Development Officer
- Eric So – General Counsel and Corporate Secretary
The board and management team collectively articulate a vision focused on transforming mental health treatment through clinically validated psychedelic medicines, with governance practices aligned to public-company disclosure standards and oversight requirements.